Advertisement
Home Tags Drug Approvals

Tag: Drug Approvals

The first artificial iris has been approved by the U.S. Food and Drug Administration for patients with aniridia.

FDA Approves First Artificial Iris

CustomFlex Artificial Iris improves light sensitivity and glare, cosmetic appearance of the eye
U.S. Food and Drug Administration approval of Xeljanz (tofacitinib) has been expanded to include adults with active moderate-to-severe ulcerative colitis

FDA Approves New Treatment for Ulcerative Colitis

First oral medication approved for chronic use in moderate-to-severe active ulcerative colitis
Palynziq (pegvaliase-pqpz) has been approved by the U.S. Food and Drug Administration to treat phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations
Aimovig (erenumab-aooe) has been approved by the U.S. Food and Drug Administration to prevent migraine headaches in adults.

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo
Doptelet (avatrombopag) has been approved by the U.S. Food and Drug Administration to treat adults with chronic liver disease who are slated to have a medical or dental procedure.

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure
Lucemyra (lofexidine hydrochloride) has been approved by the U.S. Food and Drug Administration to treat symptoms of opioid withdrawal.

FDA Approves Non-Opioid Treatment for Opioid Withdrawal

Lucemyra is an oral selective alpha 2-adrenergic receptor agonist
Retacrit (epoetin alfa-epbx) has been approved by the U.S. Food and Drug Administration as the first "biosimilar" to the anemia drugs Epogen and Procrit.

FDA Approves ‘Biosimilar’ Drug to Treat Certain Types of Anemia

Retacrit is biosimilar to the drugs Epogen and Procrit
The U.S. Food and Drug Administration has expanded its approval of the multiple sclerosis drug Gilenya (fingolimod) to include children aged 10 and older.

FDA Expands Use of MS Drug to Include Children

Gilenya is the first multiple sclerosis drug approved for children
The U.S. Food and Drug Administration has approved the new Hemospray device to help control bleeding of the gastrointestinal (GI) tract.

FDA Permits Marketing of New Device for Treating GI Bleeding

Hemospray is an aerosolized spray that delivers a mineral blend to the bleeding site
Two anti-cancer drugs administered together have been approved by the U.S. Food and Drug Administration to treat BRAF-positive anaplastic thyroid cancer.

FDA Approves Drug Combo for Aggressive Thyroid Cancer

Dabrafenib + trametinib approved to treat BRAF-positive anaplastic thyroid cancer